polypharmacy in the geriatric population
TRANSCRIPT
![Page 1: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/1.jpg)
Polypharmacy in the Geriatric Population
Maegan Rogers, PharmD, BCPS, CDEInternal Medicine Clinical Pharmacy Specialist
Regional One HealthMemphis, TN
![Page 2: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/2.jpg)
Objectives
• Define polypharmacy
• Describe risk factors for geriatric patients
• Indentify common “offending” medications
• List available screening tools for polypharmacy
• Describe ways to limit adverse drug events in the elderly population
![Page 3: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/3.jpg)
Definitions
• Geriatric Population– “Greatest generation”
– Baby Boomers?
• Polypharmacy– Prescribing multiple medications
– Five or more
• Inappropriate prescribing (IP)– Potentially inappropriate medications (PIM)
– Potential prescribing omissions (PPO)
C. Parsons. Ther Adv Drug Saf. 2017, Vol 8(1) 31-46
![Page 4: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/4.jpg)
Definitions
Adverse Drug Events (ADE)
• Unintended and undesired effects
• Five categories
– Adverse drug reaction
– Medication error
– Allergic reactions
– Withdrawal
– Overdose
https://health.gov/hcq/ade.asp. Accessed April 2019
![Page 5: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/5.jpg)
Anyone’s Grandma
![Page 6: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/6.jpg)
Anyone’s Grandma
![Page 7: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/7.jpg)
Geriatric Population
Now most live into 60s and beyond
http://www.searo.who.int/entity/health_situation_trends/data/chi/elderly-population/en/. Accessed April 2019
![Page 8: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/8.jpg)
Pharmacokinetics
• Decreased function
– Renal
– Hepatic
• First-pass clearance
• Protein binding
• Absorption
Klotz U. Drug Metabolism Reviews. 2009, 41:2, 67-76
![Page 9: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/9.jpg)
Polypharmacy in the Elderly
• 37% patients 75-85 years old
• Hospitals
– Five to eight meds – 41%
– One or more unnecessary – 59%
• > 50% nursing home residents
Maher Jr RL, et al. Expert Opin Drug Saf. 2014, Jan 13(1): doi:10.1517/14740338.2013.827660
![Page 10: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/10.jpg)
Polypharmacy in the Elderly
Negative outcomes• Greater cost• Increased ADE
– Drug interactions– Non-compliance
• Reduced functional capacity– Activities of daily living (ADLs)– Nutrition
• Multiple geriatric syndromes– Cognitive impairment– Falls– Urinary incontinence
Maher Jr RL, et al. Expert Opin Drug Saf. 2014, Jan 13(1): doi:10.1517/14740338.2013.827660
![Page 11: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/11.jpg)
Polypharmacy in the Elderly
• “Do the wrong thing for the right reason.”
– Guideline contributions
– Evidence-based medicine
• Two disease states – all it takes
– Diabetes
– Heart failure
– COPD
![Page 12: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/12.jpg)
Adverse Drug Events
Each Year Cause
• 3.5 million physician office visits
• 1 million ER visits
• 125,000 hospital admissions
– 1 in 3 hospital adverse events
– Affect 2 million hospital stays
– Prolong hospital stay 2-5 days
https://health.gov/hcq/ade.asp
![Page 13: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/13.jpg)
ADE in the Elderly
• Pharmacokinetics and polypharmacy unavoidable
• Steps to minimize
– Accurate records
– Balance polypharmacy
– Individualize doses
– Simple regimens
– Safe management by patients
– Therapeutic drug monitoring
– Inter-disciplinary
Brahma DK et al. J Pharmacol Pharmacother. 2013 Apr-Jun; 4(2): 91-94.
![Page 14: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/14.jpg)
Decreasing Polypharmacy
• Education
– Providers
– Patients
• Clinical pharmacy
– Medication therapy management
– Multidisciplinary teams
– Medical homes
• Tools
![Page 15: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/15.jpg)
Polypharmacy Screening Tools
• Beers list
• STOPP criteria
• START criteria
• Inappropriate prescribing in the elderly tool (IPET)
– Published in Canada
– 14 criteria
![Page 16: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/16.jpg)
Beers Criteria
• Potentially Inappropriate Mediciations
• Most commonly used list– Organ system
– Therapeutic category
– Drugs
• Drug-disease
• Use with caution
• Interactions
• Renal impariment
2019 AGS Beers Criteria Update Expert Panel. J Am Geriatr Soc 00:1-21, 2019
![Page 17: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/17.jpg)
Beers Medications
• Alpha-1 blockers• Amiodarone• Anticholinergics• Antidepressants
– Amitriptyline– Doxepin
• Antipsychotics• Antispasmodics• Barbiturates• Benzodiazepines• Benztropine• Clonidine• Digoxin
• Dipyridamole• Estrogen• Megestrol• Meperidine • Metoclopramide• Muscle relaxants• Nitrofurantoin• NSAIDs• Proton-pump inhibitors• Sedative hypnotics• Sulfonylureas • Testosterone
2019 AGS Beers Criteria Update Expert Panel. J Am Geriatr Soc 00:1-21, 2019
![Page 18: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/18.jpg)
STOPP Criteria
• Screening Tool of Older persons’ Potentially inappropriate Prescriptions
• 65 clinical criteria
• ADEs significantly associated
Gallagher P et al. Arch Intern Med. 2011;171(11):1013-1019
![Page 19: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/19.jpg)
![Page 20: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/20.jpg)
![Page 21: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/21.jpg)
![Page 22: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/22.jpg)
START Criteria
• Screening Tool to Alert doctors to Right Treatments
• 22 clinical criteria
• Used with STOPP criteria
• Correct treatments
Barry PJ et al. Age and Ageing. 2007; 36:632-638
![Page 23: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/23.jpg)
![Page 24: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/24.jpg)
• Prospectively over 4 months
• 600 patients– 329 ADEs in 158 patients (26.3%)
– 66.6% contributed to admission
• STOPP criteria associated with avoidable ADE (p<0.001)
• Beers criteria not associated with reduction (p=0.11)
![Page 25: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/25.jpg)
• Prospective study • Oct 2016 - April 2017• 234 patients ≥ 75 years• Pharmacist intervention• Primary outcomes
– Polypharmacy (≥ 5 drugs)– Hyperpolypharmacy (≥ 10 drugs)– Number of medications– Medication-related problems– STOPP/START criteria– Discharge
![Page 26: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/26.jpg)
![Page 27: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/27.jpg)
![Page 28: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/28.jpg)
Results• 234 patient • Medication appropriateness
– 2469 admission medications– 2344 discharge medications
• 802 drugs discontinued (32.5%)• Improvement (p ≤ 0.001)
– Polypharmacy (-10.2%, 95% CI -15.3, -5.2)– Hyperpolypharmacy (-16.6%, 95% CI -22.3 -11.0)– Number of medications (-1.4, 95% CI -1.8, -1.0)– STOPP criteria (-19.2%, 95% CI -24.9, -13.6)– START criteria (-6.8%, 95% CI -10.1, -3.5)– Medication-related problems (-2.7, 95% CI, -2.9, -2.4)
![Page 29: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/29.jpg)
Conclusions
• A systematic pharmacist-led intervention at hospital admission with a comprehensive geriatric assessment was associated with a decrease in polypharmacy, medication-related problems, and potentially inappropriate prescribing
![Page 30: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/30.jpg)
Anticholinergics
• Reduced clearance
• Tolerance
• Risk
– Confusion
– Dry mouth
– Constipation
• Diphenhydramine may be used sparingly
![Page 31: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/31.jpg)
Anticoagulants
• Warfarin– Interactions
• Antibiotics• Anticonvulsants• Amiodarone• Diet – Vitamin K• NSAIDs – Aspirin
– Monitoring– Fall/bleed risk
• Direct-oral anticoagulants– Preferred if appropriate– Still fall/bleed risk
![Page 32: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/32.jpg)
Antidiabetic
• Goal HgA1c < 7%?
• NO GLYBURIDE!!!
• Titrate insulin carefully
• Watch for hypoglycemia
• Consider ADE
– Thiazolidinediones
– SGLT2 inhibitiors
![Page 33: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/33.jpg)
Practical Considerations
• Avoid medications to treat effects of other medications
• Ask about OTC medications
• Review lists regularly
• “Start low and go slow”
• Use Beers list, STOPP, and START criteria
Pretorius RW et al. Am Fam Physician. 2013;87:331-336
![Page 34: Polypharmacy in the Geriatric Population](https://reader034.vdocuments.net/reader034/viewer/2022042707/62664cfc578d512d612982c7/html5/thumbnails/34.jpg)
Questions